Related references
Note: Only part of the references are listed.Recurrence patterns and progression-free survival after chemoradiotherapy with or without consolidation durvalumab for stage III non-small cell lung cancer
Noriko Kishi et al.
JOURNAL OF RADIATION RESEARCH (2023)
A review on epidermal growth factor receptor's role in breast and non-small cell lung cancer
Vetriselvan Subramaniyan et al.
CHEMICO-BIOLOGICAL INTERACTIONS (2022)
Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer
David R. Spigel et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (Lung ART): an open-label, randomised, phase 3 trial
Cecile Le Pechoux et al.
LANCET ONCOLOGY (2022)
Combination of SABR With Anti-PD-1 in Oligoprogressive Non-Small Cell Lung Cancer and Melanoma: Results of a Prospective Multicenter Observational Study
Rodolfo Chicas-Sett et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2022)
Outcomes with durvalumab after chemoradiotherapy in stage IIIA-N2 non-small-cell lung cancer: an exploratory analysis from the PACIFIC trial
S. Senan et al.
ESMO OPEN (2022)
Chemo-radiotherapy plus durvalumab for loco-regional relapse of resected NSCLC
Paolo Borghetti et al.
RADIATION ONCOLOGY (2022)
SPOTLIGHT real-world study: Patient characteristics and treatment patterns in patients with unresectable stage III NSCLC receiving durvalumab after chemoradiotherapy (CRT)
M. J. Mooradian et al.
ANNALS OF ONCOLOGY (2021)
Comprehensive Review of Methodology to Detect Reactive Oxygen Species (ROS) in Mammalian Species and Establish Its Relationship with Antioxidants and Cancer
Shivkanya Fuloria et al.
ANTIOXIDANTS (2021)
Real-world prospective analysis of treatment patterns in durvalumab maintenance after chemoradiotherapy in unresectable, locally advanced NSCLC patients
Julian Taugner et al.
INVESTIGATIONAL NEW DRUGS (2021)
A Real-World, Multicenter, Observational Retrospective Study of Durvalumab After Concomitant or Sequential Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer
Alessio Bruni et al.
FRONTIERS IN ONCOLOGY (2021)
P21.02 Incidence and Outcomes of Brain Metastases in Unresectable Stage III Patients with NSCLC Treated with Durvalumab after Chemoradiation
S. Patel et al.
Journal of Thoracic Oncology (2021)
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
Enriqueta Felip et al.
LANCET (2021)
Immunotherapy in association with stereotactic radiotherapy for non-small cell lung cancer brain metastases: results from a multicentric retrospective study on behalf of AIRO
Silvia Scoccianti et al.
NEURO-ONCOLOGY (2021)
Significant therapeutic effectiveness of durvalumab after chemoradiotherapy for a patient with post-operative recurrent pulmonary pleomorphic carcinoma
So Shimamura et al.
RESPIROLOGY CASE REPORTS (2021)
Salvage Therapy for Locoregional Recurrence After Stereotactic Ablative Radiotherapy for Early-Stage NSCLC
Eric D. Brooks et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Radiotherapy for local recurrence of non-small-cell lung cancer after lobectomy and lymph node dissection-can local recurrence be radically cured by radiation?
Yukihiro Terada et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2020)
Association of Long-term Outcomes and Survival With Multidisciplinary Salvage Treatment for Local and Regional Recurrence After Stereotactic Ablative Radiotherapy for Early-Stage Lung Cancer
Eric D. Brooks et al.
JAMA NETWORK OPEN (2018)